Jiangsu Bioperfectus Technologies Co., Ltd. (SHA:688399)
27.89
+0.59 (2.16%)
Sep 23, 2026, 3:00 PM CST
SHA:688399 Revenue
Jiangsu Bioperfectus Technologies had revenue of 68.84M CNY in the quarter ending June 30, 2026, a decrease of -18.02%. This brings the company's revenue in the last twelve months to 310.89M, down -10.60% year-over-year. In the year 2025, Jiangsu Bioperfectus Technologies had annual revenue of 339.05M, down -3.02%.
Revenue (ttm)
310.89M
Revenue Growth
-10.60%
P/S Ratio
11.14
Revenue / Employee
537.88K
Employees
578
Market Cap
3.46B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 339.05M | -10.56M | -3.02% |
| Dec 31, 2024 | 349.61M | -53.57M | -13.29% |
| Dec 31, 2023 | 403.18M | -5.13B | -92.72% |
| Dec 31, 2022 | 5.53B | 2.70B | 94.95% |
| Dec 31, 2021 | 2.84B | 1.10B | 63.19% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Baolingbao Biology | 2.85B |
| Qingdao Vland Biotech INC. | 1.42B |
| Beijing Kawin Technology Share-Holding | 1.23B |
| Pulike Biological Engineering | 1.02B |
| Zhejiang East Asia Pharmaceutical | 990.47M |
| Landfar Bio-medicine | 660.26M |
| Zhejiang Shouxiangu Pharmaceutical | 616.54M |
| Shanghai Model Organisms Center | 457.70M |